Answers are grounded in this paper and cite their sources.
Reported are three children with MS who responded dramatically to interferon-beta (IFNbeta) therapy. While on immunomodulatory therapy, they developed chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) that responded to IV immunoglobulin (IVIG) administration. These cases emphasize two interesting observations: 1) IFNbeta treatment did not prevent development of CIDP; 2) CIDP in the context of MS responded to IVIG, even though IVIG had no therapeutic effect on the central demyelinating disease.
No takes yet. Share an insight, caveat, or question.
Pirko et al. (2003) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: